For several days in late September 2015, heavy rains soaked the earth surrounding the district of El Cambray II in Guatemala. On the first night of the following month, steep slopes, long held in place by thick, tropical tree roots, suddenly gave way, burying hundreds of homes in mud up to 15 meters deep. At least 280 people died.
Officials had warned residents for years that the area was at risk, but a mixture of poverty and mistrust leads some of the poorest people in Central America and beyond to build and live on marginal land. Still, residents of El Cambray II might have been willing to temporarily evacuate, if they had received a credible and precise warning. And if such warnings were available worldwide, they could help reduce the 3,000 deaths attributed to landslides every year. Continue reading
When general store owner Melchor Villanueva leans on his countertop he can see his whole world under his hands. The counter’s glass surface displays photos of his community: young soccer players, teens in their coming-of-age quince años finest, and bandanna-wearing fishermen. Many descend from survivors of Hurricane Janet, which in 1955 killed a third of the population of Xcalak, a beach town on the Mexico-Belize border, and destroyed the town’s coconut plantations. “It left only sand,” Villanueva recalls. Continue reading
When pharmacologist Ravindra Ghooi learned in 1996 that his mother had terminal breast cancer, he began to investigate whether he could obtain morphine, in case she needed pain relief at the end of her life. But a morphine prescription in India at that time, even for the dying, was a rare thing: most states required four or five different licences to buy painkillers such as morphine, and there were harsh penalties for minor administrative errors. Few pharmacies stocked opioids and it was a rare doctor who held the necessary paperwork to prescribe them. Ghooi, who is now a consultant at Cipla Palliative Care and Training Centre in Pune, used his connections to ask government and industry officials if there was a straightforward way of obtaining morphine for his mother. “Everybody agreed to give me morphine,” he recalls, “but they said they’d give it to me illegally.” Continue reading
He didn’t know it at the time, but when chemist Matthew Todd posted a request for help on The Synaptic Leap, a website devoted to open-source biomedical research, he was sowing the seeds for a rivalry between an open initiative and a contract-research organization hired by the World Health Organization to reach the same goal.
The aim of both projects, run in 2010, was to produce a safer, low-cost version of praziquantel, a treatment for the tropical parasitic infection schistosomiasis. Up until that point, the treatment contained two enantiomers (mirror-image versions of the molecule that have slightly different properties) of praziquantel. One enantiomer has no effect on the parasite, but gives the drug a bitter taste. Eliminating this undesirable form could reduce side effects and help more patients to complete their treatment. The pure drug needed to be affordable. Todd, who is at the University of Sydney in Australia, thought that an open project was the best way to achieve this. “Open is very well-suited for neglected diseases,” he says. “The pay-off of secrecy is not very large.” Continue reading